Diagnostic accuracy of a novel point‐of‐care test for simultaneous detection of anti‐transglutaminase IgA and anti‐deamidated gliadin IgG antibodies

Abstract

BackgroundPoint‐of‐care tests (POCTs) may have a role in detecting undiagnosed cases of Celiac disease (CD). We assessed the diagnostic accuracy of a novel POCT, compared with the conventional serological methods, for simultaneous anti‐transglutaminase (tTG) IgA and anti‐deamidated gliadin (DGP) IgG antibody detection. Furthermore, we evaluated the effect of different biological matrices (whole blood and serum) on test performance.MethodsSerum and whole blood from celiac or suspected celiac patients who underwent duodenal biopsy were assayed for the presence of anti‐tTG IgA and anti‐DGP IgG both with the reference standard methods (Thermo Fisher Scientific, Uppsala, Sweden) and with the POCT (PRIMA Lab SA, Balerna, Switzerland).Results266 sera (101 negative and 165 positive) and 60 whole blood samples (34 positive and 26 negative) were included in the study. POCT for anti‐DGP IgG showed a sensitivity of 84.3% and a specificity of 90.1%, with positive (PPV) and negative predictive values (NPV) of 91.07% and 82.73%. POCT for anti‐tTG IgA showed a sensitivity of 98.31% and a specificity of 98.02%, with a PPV and NPV of 98.31% and 98.02%. Test accuracies were 86.94% and 98.17%, respectively. The agreement of the results between the two different matrices showed a strong correlation rate: 95% for anti‐DGP IgG and 100% for anti‐tTG IgA.ConclusionThe anti‐tTG IgA/anti‐DGP IgG‐based POCT showed good diagnostic accuracy with comparable sensitivities and specificities to reference standard methods in detecting CD in symptomatic patients and could be considered as a mass screening test before referring to conventional serology.